Sponsor:
Astellas Pharma Global Development, Inc.
Code:
NCT06901531
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
zolbetuximab
Pembrolizumab
Capecitabine
Oxaliplatin
Folinic acid (leucovorin or local equivalent)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-31. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2025-12-04.